BioSpace News Archive

Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) of the face or scalp and it acts through a selective antiproliferative mechanism of action

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Ministry of Food and Drug Safety of South Korea (MFDS) has approved the Company’s application for Conditional Marketing Authorization for its mRNA vaccine against COVID-19.

- For Use of Subcutaneous Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (D-VCd) in Newly Diagnosed Adult Patients with Systemic Light Chain (AL) Amyloidosis - - For Use of Subcutaneous Daratumumab in Combination with Pomalidomide and Dexamethasone (D-Pd) in Adult Patients with Relapsed or Refractory Multiple Myeloma -

Health Data Analytics Institute (HDAI) – an innovator in healthcare AI solutions – and researchers at Dana-Farber Cancer Institute today announced publication of findings exploring the effectiveness of immune checkpoint inhibition for the treatment of Medicare patients with lung cancer.

PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON TUESDAY MAY 25, 2021 ON MASITINIB’S RESULTS IN PROSTATE CANCER Paris, May 21, 2021, 6pm CET

New Travelers’ Diarrhea (TD) severity classification tool, developed with the University of Texas Houston School of Public Health, provides clear separation of clinical severity categories and prognostic information for TD resolution with potential utility in clinical practice

The panel discussion, led by Dr. Jason McCarthy, Maxim’s Senior Managing Director of Biotechnology Equity Research, and including other voices in the healthcare industry, will cover exciting topics in AD drug development.

K-One MediTech To Begin Production of CE approved 15-Minute Antigen Test Solution

Clinical Enterprise, Inc. d/b/a empowerDX, today announced its at-home COVID-19 testing kit received FDA-emergency use authorization for children three years and older.

Syneos Health®, the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences